Compare TROW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TROW | INSM |
|---|---|---|
| Founded | 1937 | 1988 |
| Country | United States | United States |
| Employees | 4802 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 22.4B |
| IPO Year | 2000 | 2000 |
| Metric | TROW | INSM |
|---|---|---|
| Price | $102.06 | $142.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | $104.57 | ★ $194.18 |
| AVG Volume (30 Days) | 1.9M | ★ 3.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.96% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 7.89 | N/A |
| Revenue | ★ $2,370,700,000.00 | N/A |
| Revenue This Year | $5.99 | $206.90 |
| Revenue Next Year | $1.02 | $60.68 |
| P/E Ratio | $13.30 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $85.22 | $90.39 |
| 52 Week High | $122.00 | $212.75 |
| Indicator | TROW | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 74.43 |
| Support Level | $100.47 | $135.73 |
| Resistance Level | $106.66 | $142.90 |
| Average True Range (ATR) | 3.37 | 7.04 |
| MACD | -0.64 | 3.18 |
| Stochastic Oscillator | 1.86 | 83.03 |
T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of August 2026, the firm had $1.897 trillion in managed assets, composed of equity (48%), balanced (37%), fixed-income and money market (12%), and alternative (3%) offerings. Close to two-thirds of managed assets are held in retirement-based accounts, which provide T. Rowe Price with a stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.